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Abstract 
Missense and frameshift mutations in TANK-binding kinase 1 (TBK1) have been 
reported in European sporadic and familial amyotrophic lateral sclerosis (ALS) 
cohorts. To assess the role of TBK1 in ALS patient cohorts of wider ancestry, we 
have analysed whole exome sequence data from an Australian cohort of familial ALS 
patients and controls. We identified a novel TBK1 deletion (c.1197delC) in a familial 
ALS patient of Chinese origin. This frameshift mutation (p.L399fs) likely results in a 
truncated protein that lacks functional domains required for adapter protein binding, 
as well as protein activation and structural integrity. No novel or reported TBK1 
mutations were identified in familial ALS patients of European ancestry. This is the 
first report of a TBK1 mutation in an ALS patient of Asian origin and indicates that 
sequence variations in TBK1 are a rare cause of familial ALS in Australia. 
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1. Introduction 
Amyotrophic lateral sclerosis (ALS, also known as motor neuron disease, MND) is a 
fatal neurodegenerative disease that is characterised by the rapidly progressive 
degeneration of the upper and lower motor neurons. The progression of paralysis is 
profound, rapidly leading to death, usually from respiratory failure within 2 to 5 years 
of first symptoms. To date the only known cause of ALS are gene mutations, which 
have been reported in more than 20 genes (ALS Online Database (ALSoD 6.0 at 
http://alsod.iop.kcl.ac.uk) (Abel, et al., 2013) and reviewed in Renton, et al. (2014)). 
Much of our understanding of disease pathology has stemmed from genetic 
discoveries in the hereditary form of the disease (familial ALS). Gene discovery in 
ALS has long comprised of multi-generational pedigree analyses using exome 
sequencing and/or linkage analysis to identify causative mutations. More recently, 
gene discovery strategies in ALS have included statistical genetic analyses of large 
cohorts of probands, including both familial and sporadic cases.  
The TANK-binding kinase 1 (TBK1) gene was recently reported as an ALS 
gene through rare variant enrichment analyses (Cirulli, et al., 2015) and familial 
discovery studies (Freischmidt, et al., 2015). Several ALS-linked mutations have 
been identified in this gene, predominantly insertions/deletions that result in 
frameshift mutations and truncated proteins. Cirulli, et al. (2015) used whole exome 
sequence data from a large cohort of ALS patients (both familial and sporadic cases) 
and controls to observe for enrichment of genetic-model-specific variants in patients. 
They used a gene-based collapsing analysis across six genetic models including 
dominant coding, recessive coding, dominant not benign, recessive not benign, 
dominant loss of function, and recessive loss of function. Using a discovery dataset 
of 2843 cases and 4310 controls, 51 genes (including TBK1) showed association 
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with ALS and were taken forwards for replication. Interestingly, OPTN was the only 
previously known ALS gene among the 51 genes. The replication dataset of 1318 
cases and 2371 controls confirmed TBK1 as an ALS gene with significant variant 
enrichment in cases compared to controls, in both the discovery and replication 
datasets in the dominant not benign genetic model. In the discovery dataset, TBK1 
was ranked fourth, third and third in dominant coding, dominant not benign and 
dominant loss of function genetic models respectively. In total, 11 novel loss of 
function and 21 novel missense variants in TBK1 were identified in patients. 
Freischmidt, et al. (2015) also recently reported rare variant enrichment 
analysis in 252 familial ALS cases of European descent. They too used a collapsing 
method combined with multivariate tests (Li and Leal, 2008) to identify significant 
enrichment of loss of function variants in TBK1 in familial ALS patients when 
compared to controls. However, targeted mutation screening of TBK1 in 1010 
sporadic ALS cases and 650 additional controls did not show similar enrichment of 
loss of function variants. Combined, Freischmidt, et al. (2015) identified 8 different 
loss of function variants and 9 different missense variants in TBK1 in ALS patients. 
Several of the families with TBK1 loss of function variants described in this study 
have comorbid ALS and/or frontotemporal dementia (FTD)/cognitive impairment. 
Further functional analysis suggested that haploinsufficiency is the most likely 
pathogenic mechanism underlying these loss of function variants. Since Freischmidt, 
et al. (2015) identified TBK1 mutations in 4% of genetically unexplained FALS, they 
suggested that TBK1 mutations may be a common genetic cause among 
Caucasians with ALS.  
 To determine the overall contribution of this particular gene to ALS across 
multiple ethnicities, mutation screening in extended geographical cohorts is required. 
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We have examined TBK1 variants in a cohort of Australian familial ALS cases and 
identified a previously unreported single base pair deletion, resulting in a frameshift 
mutation, in an Australian patient of Chinese origin. The patient had limb onset and 
developed cognitive impairment with language disturbance, however they were not 
formally diagnosed with FTD. As all previous ALS-linked TBK1 mutations have been 
identified in European cases, this is the first report of a TBK1 mutation in an ALS 
patient of non-European origin. No novel TBK1 variants were identified in ALS 
patients of European background. 
 
2. Material and methods 
2.1 Participants 
We analysed a total of 127 individuals from 94 Australian ALS families. Freischmidt, 
et al. (2015) reported segregation of loss of function TBK1 variant and a pathogenic 
FUS missense variant in a single patient, therefore we included 39 patients who 
were positive for a mutation in a known ALS gene to prevent omitting possible 
oligogenic cases (van Blitterswijk, et al., 2012). The remaining 88 patients (from 75 
families) were negative for known ALS genes. It should be noted that 89/127 cases, 
excluding the discovery case described here, are part of the FALS sequencing 
consortium described in Cirulli, et al. (2015). Samples were recruited from Molecular 
Medicine Laboratory at Concord Hospital, the Australian MND DNA bank and from 
the Macquarie University MND Biobank. Patients, family members and unrelated 
controls were recruited under informed written consent as approved by the 
institutional review boards of the participating institutions. Patients were diagnosed 
with definite or probable ALS according to El Escorial criteria (Brooks, et al., 2000). 
Patients had previously been screened for mutations/expansions in known ALS 
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genes including TARDBP, SOD1, FUS, UBQLN2, PFN1, VCP, OPTN and 
C9ORF72.  
 
2.2 Genetic analysis 
Patient exomes were captured using the TruSeq Exome Enrichment kit or Agilent 
SureSelectXT Human All Exon V5+UTR. Paired-end sequencing was performed 
using the Illumina HiSeq2000 instrument. Read depth of each exon in TBK1 was 
calculated using QualiMap v.2.0.2 (Garcia-Alcalde, et al., 2012). TBK1 variants were 
identified in exome sequence data using custom bioinformatic scripts. Validation of 
the identified TBK1 deletion (c.1197delC) was performed by direct DNA sequencing 
following PCR amplification of NM_013254 exon 10 (primers: forward 5’-
CGAAAACTACATTACAGATTTTGCC-3’ and reverse 5’-
ACTTGGAAAGGGTATCAATTTAAG-3’). PCR products were Sanger sequenced 
using Big-Dye terminator sequencing and an ABI 3730XL DNA analyser (Applied 
Biosystems).  
The public SNP databases were accessed at: dbSNP Build 141 
(http://www.ncbi.nlm.nih.gov/SNP/), the 1000 Genomes Project 
(http://www.1000genomes.org/), the Exome Variant Server, NHLBI GO Exome 
Sequencing Project (ESP, http://evs.gs.washington.edu/EVS/) and Exome 
Aggregation Consortium (ExAC, http://exac.broadinstitute.org). Control exome 
sequence data was obtained (using the same method described above) from 967 
neurologically healthy individuals of predominantly Western European descent from 
the Diamantina Control Cohort (University of Queensland Diamantina Institute, 
University of Queensland, Australia). 
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3. Results 
3.1 Identification of a novel TBK1 frameshift mutation 
We examined whole exome sequence data from familial ALS patients and controls to 
determine the frequency of TBK1 mutations in Australian familial ALS. Exome 
sequencing achieved a mean read depth of >60X across all TBK1 coding exons. We 
identified an unreported frameshift mutation in TBK1 (c.1197delC, p.L399fs) in an 
Australian ALS patient of Chinese origin (Fig. 1B). The mutation is absent from all 
public SNP databases including dbSNP141, the 1000 Genomes Project, the NHLBI 
Exome Sequencing Project (ESP) exome variant server and Exome Aggregation 
Consortium (ExAC) and the Diamantina Control Cohort. The frameshift deletion is 
predicted to result in a truncated protein of 407 amino acids (Fig. 1C). No DNA was 
available from other family members. No tissue was available to assess transcription 
of the mutant allele. Bioinformatic analysis using MutationTaster (Schwarz, et al., 
2014) and SIFT version 5.2.2 (Kumar, et al., 2009) predicted that the mutation would 
lead to nonsense mediated decay of the mutant transcript. 
Two unreported TBK1 missense variants were identified in the Diamantina 
Control Cohort in exon 3 (c.A217G, p.I73V; minor allele frequency, MAF = 0.001) 
and exon 10 (c.A1201G, p.K401E; MAF = 0.0005). These variants are absent from 
public SNP databases including dbSNP141, the 1000 Genomes Project, and the 
NHLBI Exome Sequencing Project (ESP) exome variant server, however were 
present in ExAC at MAF values of 0.00004 and 0.00001 respectively (no further 
clinical information is available on these control subjects). 
 
3.2 Clinical presentation of the TBK1 frameshift mutation family 
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The proband (III:1; Fig. 1A) is from a three-generation family of Chinese origin in 
which the proband and his mother had ALS and two maternal uncles and maternal 
grandfather have historical diagnoses of Parkinson’s Disease (Fig. 1A). The proband 
had a long standing history of bronchiectasis secondary to pneumonia as a child.  He 
also had a six-year history of mild depression, and a two-year history of complex 
partial seizures controlled with carbemazepine. At age 60 he developed progressive 
right arm weakness and, after two years, was referred to a neurologist. At 
presentation he had global weakness in the right arm associated with cramp on 
muscle activation. There was no weakness in the left arm or legs, although he had 
lost five kilograms in weight over the previous 12 months. There was no cranial 
nerve or cognitive involvement at presentation. Physical examination revealed 
widespread muscle atrophy, generalised fasciculations and focal weakness in the 
right upper limb, with normal tone and deep tendon reflexes. There were no other 
upper motor neuron signs, and no involvement of the left upper limb or legs. 
Neurophysiology confirmed widespread denervation and re-innervation consistent 
with a motor neuronopathy. Magnetic resonance imaging of the brain and spinal cord 
was normal. Biochemistry including creatine phosphokinase was normal.   
The proband progressed with weakness in the upper limbs and subsequently 
the lower limbs over the next three years. He developed progressive respiratory 
failure due to a combination of his pre-existing bronchiectasis and respiratory muscle 
weakness. He began non-invasive ventilation at night that increased to 24-hour use 
over the next year. He developed cognitive problems with impairment of short-term 
memory and recall, as well as subsequent language disturbance with word finding 
difficulty, speech arrest and errors in syntax and grammar. Formal cognitive 
assessment was not performed. With progressive respiratory failure and limb 
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weakness, he died at age 66, 44 months after diagnosis and 68 months after 
symptom onset. 
The proband’s mother, II:1; Fig. 1A, initially had symptoms of spastic 
weakness in her right leg at age 73. Six months later, her left leg also developed a 
progressive spastic weakness. Sensory examination was normal. Eighteen months 
after first symptoms, she had slight right foot drop with evidence of bilateral 
spasticity. Deep tendon reflexes were overall increased in the legs, more so in the 
right leg. Plantar responses were flexor, but sustained clonus was noted on the right 
and unsustained on the left. In her upper limbs, power, tone and coordination was 
normal and there was no evidence of fasciculations. Lower motor neuron signs were 
absent at this stage. 
Over the next 6 months, she had progressive difficulty in using her hands and 
fingers, with fasciculations present in all four limbs. Speech and swallowing was 
normal at this stage. Other lower motor neuron signs were still absent, but the 
combination of fasciculations, weakness and upper motor neurone signs resulted in 
a diagnosis of amyotrophic lateral sclerosis. No further clinical information was 
available for the final 5 years of her disease progression. She died at age 82, six 
years after diagnosis and eight years after symptom onset.  
The proband’s maternal grandfather (I:1; Fig. 1A) was reported to have had 
walking difficulties and Parkinson’s disease because of a tremor. Similarly, the 
proband’s maternal uncle, II:3, was reported to have shaking in the limbs, walking 
difficulties and Parkinson’s disease. 
 
4. Discussion 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 10
Here we describe a novel TBK1 truncating mutation in an Australian familial ALS 
patient of Chinese origin. The normal TBK1 protein comprises 729 amino acids and 
this frameshift mutation truncates the protein by 44% to 407 amino acids. The 
truncated protein retains the N-terminal kinase domain (KD) and the ubiquitin-like 
domain (ULD) however lacks the entire α-helical scaffold and dimerization domain 
(SDD) and the C-terminal domain (Fig. 1C) (Larabi, et al., 2013,Tu, et al., 2013). As 
such, structural integrity of the protein and its adapter protein binding may be 
hindered. 
 Normal TBK1 functions as a dimer through extensive hydrophobic contact 
between the ULD and SDD (Larabi, et al., 2013,Tu, et al., 2013). However since the 
truncated protein does not contain the SDD, it is unlikely to form this native dimer 
conformation and would thereby remain inactive. 
Activation of TBK1 requires polyubiquitination of amino acids K30 and K401 
(Tu, et al., 2013). Interestingly, one of the missense variants (p.K401E) identified in 
the Diamantina control cohort is located at one of these polyubiquitination sites, with 
unknown consequence. This rare variant was also present in a public SNP database. 
A major functional consequence of the described frameshift mutation would 
be impairment of TBK1 binding to the adapter proteins TANK, NAP1, SINTBAD, and 
optineurin (coded by OPTN) (Larabi, et al., 2013). The C-terminal domain structurally 
extends away from the KD-ULD-SDD dimer complex (Larabi, et al., 2013) and binds 
to the adapter proteins (Goncalves, et al., 2011). Immunoprecipitation and GST pull-
down assay experiments performed by Freischmidt, et al. (2015) showed that 
mutations in the C-terminal domain render TBK1 unable to bind optineurin. 
Cirulli, et al. (2015) and Freischmidt, et al. (2015) identified multiple truncation 
and missense mutations scattered throughout the entire TBK1 protein, in all four 
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functional domains. Cirulli, et al. (2015) identified 11 loss of function mutations in 
ALS patients, with most falling within the SDD, and the remainder upstream of the 
SDD. Seven of the eight TBK1 loss of function mutations identified in familial ALS 
patients by Freischmidt, et al. (2015) also lie within or upstream of the SDD. 
Similarly, the p.L399fs frameshift mutation described here lies upstream of the SDD, 
providing additional evidence for its pathogenic role. 
Haploinsufficiency of TBK1 has been shown to lead to ALS and FTD (Cirulli, 
et al., 2015, Freischmidt, et al., 2015), while duplication of TBK1 results in 
overexpression of TBK1 leading to normal tension glaucoma, a neurodegenerative 
disorder involving the optic nerve (Kawase, et al., 2012). This suggests that TBK1 
gene dosage is critical for normal function. Previously reported data from patient cell 
lines showed no expression of the mutant TBK1 alleles at the mRNA or protein level 
for all loss of function mutations that fall within or upstream of the SDD (Freischmidt, 
et al., 2015). As such, the mutation described here would likely also lead to dosage 
effects through the generation of a non-functional protein or via nonsense mediated 
decay. 
 Normal tension glaucoma caused by TBK1 duplication (Shields, 2008) is part 
of a continuum of optic nerve neurodegenerative disorders with primary open-angle 
glaucoma (Shields, 2008) caused by mutations in OPTN (Rezaie, et al., 2002). 
Missense and nonsense mutations in OPTN have also been identified in familial and 
sporadic ALS cases (Maruyama, et al., 2010).  
The discovery family in this study presented with ALS and Parkinson’s 
disease (Fig. 1A). The proband had limb-onset ALS with cognitive impairment and 
68 month disease duration. The proband’s mother also had limb-onset ALS with 
predominant upper motor neuron involvement and a long disease duration (>96 
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months). The two maternal uncles and maternal grandfather have historical 
diagnoses of Parkinson’s disease and should therefore be taken with caution. 
Unfortunately no DNA or tissue was available from any of these patients to 
determine whether they also harboured the TBK1 p.L399fs mutation. The two 
neurodegenerative phenotypes seen in this family, coupled with TBK1 duplications 
found in normal tension glaucoma (Kawase, et al., 2012) and TBK1 mutations in 
FTD patients (Freischmidt, et al., 2015) broadens the phenotype of TBK1-associated 
neurodegenerative disease. However, further assessment of TBK1 is required in 
other neurodegenerative disorders, including Parkinson’s disease. 
No novel or reported TBK1 mutations were found in patients of European 
ancestry within the Australian ALS cohort. Our discovery of a TBK1 mutation in an 
ALS case of Asian origin suggests that a screen of TBK1 is warranted in ALS 
cohorts of non-European ancestry.  
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Figure legend 
 
Figure 1. TBK1 deletion mutation in an Australian ALS family. A. Pedigree of the 3-
generation discovery family. The arrow indicates the proband. Males are shown by 
squares, females by circles. Individuals with a diagonal line are deceased. Symbols 
filled with black represent ALS, filled with grey represent Parkinson’s disease. B. 
Sequence chromatograms showing the two alleles, the resultant amino acids for this 
section of protein and the premature stop codon in the mutant allele. C. 
Diagrammatic representation of wildtype TBK1 and the predicted truncated protein. 
Functional domains include N-terminal kinase domain (KD), the ubiquitin-like domain 
(ULD), α-helical scaffold and dimerization domain (SDD) and the C-terminal domain 
(CTD) (Larabi, et al., 2013,Tu, et al., 2013). 
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Highlights 
• A novel TBK1 truncating mutation was identified in an Australian familial 
ALS patient 
• This is the first report of a TBK1 mutation in an ALS patient of Asian origin 
• TBK1 mutations are a rare cause of ALS in Australia 
 
